Cho-Hung Chiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cho-Hung Chiang has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Yu-Cheng Chang
Department of Medicine, Danbury Hospital, Danbury, USA
11 shared publicationsKuan-Yu Chi
Albert Einstein College of Medicine
8 shared publicationsJunmin Song
Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
7 shared publicationsYu Chang
National Cheng Kung University Hospital
6 shared publicationsYuan Ping Hsia
Department of Family Medicine, Taipei Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation New Taipei City Taiwan
6 shared publicationsCho-Han Chiang
Northwell Health Cancer Institute, Lake Success, USA
5 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 178
Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis
- 12 October 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 178
Open AccessGlucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis
- 10 August 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (10) , 2368-2371
BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score–matched analysis
- 10 August 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (10) , 2368-2371
BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score–matched analysis
- 15 June 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 8693-8696
Semaglutide and Risk of Pancreatic Cancer: A Meta‐Analysis of Randomised Trials
- 15 June 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (9) , 8693-8696
Semaglutide and Risk of Pancreatic Cancer: A Meta‐Analysis of Randomised Trials
- Open Access
- 29 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (1) , 14-24
Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism
Venous thromboembolism (VTE) is a frequent occurrence in patients with cancer. However, it is not known whether treatment with different classes of anticoagulants impacts the risk of subsequent arterial thromboembolism. We performed a retrospective, population-based cohort study using Surveillance, Epidemiology, and End Results data linked with Medicare claims. Patients were eligible for study inclusion if they had a diagnosis of primary brain, colorectal, gastric, pancreatic, lung, or ovarian cancer between 2007 and 2015, were diagnosed with VTE, and had a prescription claim for a direct oral anticoagulant (DOAC), low-molecular-weight heparin (LMWH), or warfarin. We matched patients by propensity score in a 1:1:1 ratio into anticoagulant treatment groups based on their baseline demographic information, cancer-specific characteristics, and cardiovascular comorbidities. The primary aim of the study was to determine and compare the 6-month cumulative incidence of ischemic stroke across anticoagulant classes. The study comprised 4875 total patients with 1625 in each treatment group. At 6 months, the cumulative incidence of ischemic stroke was 5.6% (95% confidence interval [CI], 5.0-6.3) overall and 6.8% (95% CI, 5.6-8.1) in the DOAC, 4.9% (95% CI, 3.9-6.0) in the LMWH, and 5.2% (95% CI, 4.1-6.2) in the warfarin treatment groups (P = .040). We identified hypertension (odds ratio [OR], 1.75), atrial fibrillation/flutter (OR, 1.37), DOAC use (OR, 1.36), and previous stroke (OR, 3.59) as statistically significant risk factors for ischemic stroke in the multivariable modeling. In conclusion, ischemic stroke is a common occurrence after cancer-associated VTE and may occur more frequently in patients treated with DOACs.
- 29 December 2025
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (1) , 14-24
Open AccessComparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism
Venous thromboembolism (VTE) is a frequent occurrence in patients with cancer. However, it is not known whether treatment with different classes of anticoagulants impacts the risk of subsequent arterial thromboembolism. We performed a retrospective, population-based cohort study using Surveillance, Epidemiology, and End Results data linked with Medicare claims. Patients were eligible for study inclusion if they had a diagnosis of primary brain, colorectal, gastric, pancreatic, lung, or ovarian cancer between 2007 and 2015, were diagnosed with VTE, and had a prescription claim for a direct oral anticoagulant (DOAC), low-molecular-weight heparin (LMWH), or warfarin. We matched patients by propensity score in a 1:1:1 ratio into anticoagulant treatment groups based on their baseline demographic information, cancer-specific characteristics, and cardiovascular comorbidities. The primary aim of the study was to determine and compare the 6-month cumulative incidence of ischemic stroke across anticoagulant classes. The study comprised 4875 total patients with 1625 in each treatment group. At 6 months, the cumulative incidence of ischemic stroke was 5.6% (95% confidence interval [CI], 5.0-6.3) overall and 6.8% (95% CI, 5.6-8.1) in the DOAC, 4.9% (95% CI, 3.9-6.0) in the LMWH, and 5.2% (95% CI, 4.1-6.2) in the warfarin treatment groups (P = .040). We identified hypertension (odds ratio [OR], 1.75), atrial fibrillation/flutter (OR, 1.37), DOAC use (OR, 1.36), and previous stroke (OR, 3.59) as statistically significant risk factors for ischemic stroke in the multivariable modeling. In conclusion, ischemic stroke is a common occurrence after cancer-associated VTE and may occur more frequently in patients treated with DOACs.
- 17 September 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (12) , 1023-1026
Impact of weight status on risk of venous thromboembolism associated with GLP-1 receptor agonists
- 17 September 2025
- Published by Taylor & Francis in Expert Review of Hematology
- Vol. 18 (12) , 1023-1026
Impact of weight status on risk of venous thromboembolism associated with GLP-1 receptor agonists
- 2 July 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (11) , 3527-3539
Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials
- 2 July 2025
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (11) , 3527-3539
Glucagon-like peptide 1 receptor agonists and risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials
- Top Cited Papers
- 9 June 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (6) , 1268-1281
Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis
- 9 June 2025
- Published by Elsevier in Gastroenterology
- Vol. 169 (6) , 1268-1281
Top Cited PapersGlucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis